Displaying 1 - 1 of 1
| Active Ingredient | LAMIVUDINE | ZIDOVUDINE |
| Therapeutic Class | ANTIRETROVIRALS MISCELLANEOUS |
| Indications | Indicated in combination with other antiretroviral agents for the treatment of HIV infection. |
| Caution | Headache, fatigue, nausea, vomiting, diarrhoea, neutropenia, anemia, neuropathy , insomnia, nasal symptoms and musculoskeletal pain. |
| Dose Range | Adult and Children 12 years and over: One tablet twice daily (150mg lamivudine/300mg zidovudine per tablet). Not recommended in children under 12 y ears. |
| Drug Interactions | |
| Pregnancy | The incidence and clinical significance of mitochondrial dysfunction after in ut More ... |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |